Maggie Fung
Positions
- Clinical Coordinator, APCRC-Q
- Member, IHBI, QUT
Contact Details
- maggie.fung@qut.edu.au
- Phone
- +61 7 3176 7449
- Linkedin profile
- http://www.linkedin.com/pub/maggie-fung/42/773/2a
Related websites and profiles
Qualifications
- PhD, Drug resistance in testicular cancer, University of Hong Kong, Hong Kong, 2007
- MPhil, Blood cancer, University of Hong Kong, Hong Kong, 2001
- BSc (Hons) in Applied Biology with Biotechnology, The Hong Kong Polytechnic University, Hong Kong
Biography
After receiving her PhD degree in drug resistance in testicular cancer, Dr Fung was recruited by Johnson & Johnson as a Clinical Research Associate in Hong Kong. She was responsible for initiating and coordinating global oncology studies. This role roused her interest in clinical trials.
Dr Fung joined the APCRC – Q as Clinical Coordinator in 2009. Her major roles are to: coordinate all aspects of clinical trials for prostate cancer, run within the Multidisciplinary Prostate Cancer Clinical Trials Unit, liaise with national and international groups initiating prostate cancer clinical trials, prepare trial documents for ethics and regulatory submission, ensure complete, accurate and comprehensive records for monitoring, maintain and provide case record forms to sponsors, and facilitate recruitment of patients to trials.
Research interests
circulating tumour cells, CTC testing services for clinical studies involving Australian and international universities and pharmaceutical companies, coordinating a clinical trial with a Malaysian-based natural product company
Current research projects
Clinical study
Analysis of Biomarkers from Circulating Tumour Cells and Exosomes to Monitor Prostate Cancer Progression and Treatment Resistance
Top publications
- Fung MK, Han HY, Leung SC, Cheung HW, Cheung AL, Wong YC, Ling MT, Wang X. MAD2 interacts with DNA repair proteins and negatively regulates DNA damage repair. J Mol Biol. 2008; 24-34
- Fung MK, Cheung HW, Wong HL Yuen, HF, Ling MT, Chan KW, Wong YC, Cheung AL, Wang X. MAD2 expression and its significance in mitotic checkpoint control in testicular germ cell tumour. Biochim Biophys Acta. 2007; 1773:821-32
- Fung MK, Cheung HW, Ling MT, Cheung AL, Wong YC, Wang X. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells. Br J Cancer. 2006; 95:475-84
- Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and gial reactivation in the retina of db/db mice. Diabetes. 2005; 3119-25
- Fung MK, Au WY, Liang R, Srivastava G, Kwong YL. Aberrant promoter methylation in gastric lymphoma. Haematologica-The Hematology Journal. 2003; 231-2
Collaborators
- Dr Edwin Wong, Research Fellow, Epworth HealthCare, Melbourne
- Dr Amol Wagholikar, Project Leader, The Australian e-Health Research Centre
- Dr Margot Lehman, PAH
- Dr Simon Wood, PAH
- Study group in A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinoma (EVERSUN)
